[go: up one dir, main page]

TR200001132A2 - İmalat maddeleri - Google Patents

İmalat maddeleri

Info

Publication number
TR200001132A2
TR200001132A2 TR2000/01132A TR200001132A TR200001132A2 TR 200001132 A2 TR200001132 A2 TR 200001132A2 TR 2000/01132 A TR2000/01132 A TR 2000/01132A TR 200001132 A TR200001132 A TR 200001132A TR 200001132 A2 TR200001132 A2 TR 200001132A2
Authority
TR
Turkey
Prior art keywords
inhibition
pde5
phosphodiesterase
present
relates
Prior art date
Application number
TR2000/01132A
Other languages
English (en)
Other versions
TR200001132A3 (tr
Inventor
Thomas Emmick Jeffrey
Michael Ferguson Kenneth
Ernest Pullman William
Steven Whitaker John
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200001132(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of TR200001132A3 publication Critical patent/TR200001132A3/tr
Publication of TR200001132A2 publication Critical patent/TR200001132A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Glass Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Mevcut bulus, yüksek derecede selektif fosfodiesteraz (PDE) enzim inhibitörleriyle ve bunlari farmasötiküretim maddeleri olarak kullanimlariyla ilgilidir. Mevcut bulus özellikle, siklik guanozin 3',5'-monofosfat spesifik fosfodiesteraz tür 5 (PDE5) kuvvetli inhibitörleriyle ilgili olup bu inhibitörler, farmasötik bir ürüne yaklasik 1 ila yaklasik 20 mg birim dozajda ilave edildiginde cinsel islev bozukluklarinin tedavisinde kullanislidir. Burada açiklanan üretim maddelerinin belirleyici özelligi selektif PDE5 inhibisyonu ve dolaysiyla PDE5 inhibisyonunun arzu edildigi terapötik alanlarda fayda saglanmasi ve ayni zamanda, baska fosfodiesteraz enzimlerinin inhibisyonundan kaynaklanan aksi yan etkilerinin en aza indirgenmesi veya bertaraf edilmesidir.
TR2000/01132A 1999-04-30 2000-04-26 İmalat maddeleri TR200001132A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (2)

Publication Number Publication Date
TR200001132A3 TR200001132A3 (tr) 2001-01-22
TR200001132A2 true TR200001132A2 (tr) 2001-01-22

Family

ID=22452153

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01132A TR200001132A2 (tr) 1999-04-30 2000-04-26 İmalat maddeleri

Country Status (47)

Country Link
EP (2) EP1415652A3 (tr)
JP (2) JP4975214B2 (tr)
KR (2) KR20010020779A (tr)
CN (2) CN1196487C (tr)
AT (1) ATE251908T1 (tr)
AU (3) AU769946C (tr)
BE (1) BE1012957A5 (tr)
BR (2) BR0003046A (tr)
CA (2) CA2307101C (tr)
CH (2) CH692478A5 (tr)
CO (1) CO5170493A1 (tr)
CZ (1) CZ296534B6 (tr)
DE (3) DE10021266A1 (tr)
DK (2) DK200000677A (tr)
DZ (1) DZ3171A1 (tr)
EA (2) EA005416B1 (tr)
ES (2) ES2187234A1 (tr)
FI (1) FI20000976A7 (tr)
FR (1) FR2795646B1 (tr)
GB (1) GB2351663A (tr)
GR (1) GR1003575B (tr)
HK (1) HK1041204B (tr)
HR (2) HRP20000243A2 (tr)
HU (2) HUP0001632A3 (tr)
ID (1) ID25704A (tr)
IE (1) IE20000315A1 (tr)
IL (3) IL135817A0 (tr)
IT (1) ITMI20000922A1 (tr)
LT (1) LT4758B (tr)
LU (1) LU90569B1 (tr)
LV (1) LV12560B (tr)
MX (2) MXPA00003997A (tr)
NL (1) NL1015027C2 (tr)
NO (2) NO20002097L (tr)
NZ (2) NZ504163A (tr)
PE (1) PE20010071A1 (tr)
PL (2) PL339897A1 (tr)
PT (2) PT1173181E (tr)
SE (1) SE0001518L (tr)
SG (1) SG98384A1 (tr)
SI (2) SI20361A (tr)
SK (1) SK285415B6 (tr)
SV (1) SV2002000055A (tr)
TR (1) TR200001132A2 (tr)
UA (1) UA72248C2 (tr)
WO (1) WO2000066099A2 (tr)
ZA (2) ZA200002058B (tr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0012863A (pt) * 1999-08-03 2002-04-16 Lilly Icos Llc Composições farmacêuticas de "beta"-carbolina
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
EP1289990A1 (en) * 2000-06-08 2003-03-12 Lilly Icos LLC Tetracyclic diketopierazine compounds as pdev inhibitors
CA2423357C (en) * 2000-08-02 2008-05-27 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
ATE360422T1 (de) * 2001-06-05 2007-05-15 Lilly Icos Llc Tetrazyklische verbindungen als pde5-inhibitoren
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR101663238B1 (ko) 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
EP3749370B1 (de) * 2018-02-07 2025-05-07 Smawa GmbH Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
KR20000010918A (ko) 1996-05-10 2000-02-25 게리 엘. 윌콕스 카르볼린 유도체
PL336586A1 (en) * 1997-04-25 2000-07-03 Pfizer Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
WO2000020033A1 (en) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
EP1161255A4 (en) * 1999-03-08 2002-07-17 Merck & Co Inc METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
WO2000066114A1 (en) * 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder

Also Published As

Publication number Publication date
ES2187234A1 (es) 2003-05-16
IL135817A0 (en) 2001-05-20
KR100577057B1 (ko) 2006-05-10
AU4490800A (en) 2000-11-17
SI20361A (sl) 2001-04-30
BR0010181A (pt) 2003-02-25
NO20002097L (no) 2001-10-26
CN1196487C (zh) 2005-04-13
CN1384746A (zh) 2002-12-11
SE0001518L (sv) 2000-10-31
JP2002543116A (ja) 2002-12-17
SG98384A1 (en) 2003-09-19
HRP20010778B1 (en) 2005-04-30
SK285415B6 (sk) 2007-01-04
ZA200002058B (en) 2000-11-02
AU3012900A (en) 2000-11-02
PT1173181E (pt) 2004-02-27
LV12560A (en) 2000-11-20
NO20015275L (no) 2001-12-06
DE60005940D1 (de) 2003-11-20
HU0200912D0 (en) 2002-04-29
NO322013B3 (no) 2017-11-06
NL1015027A1 (nl) 2000-10-31
CZ20013879A3 (cs) 2002-04-17
CO5170493A1 (es) 2002-06-27
CH1173181H1 (tr) 2019-07-15
NO322013B1 (no) 2006-08-07
FI20000976L (fi) 2000-10-30
FI20000976A0 (fi) 2000-04-26
GB2351663A (en) 2001-01-10
CA2307101C (en) 2003-01-28
SV2002000055A (es) 2002-07-03
NL1015027C2 (nl) 2001-02-14
HUP0200912A3 (en) 2003-07-28
FR2795646B1 (fr) 2002-08-16
EP1173181B3 (en) 2015-03-25
ITMI20000922A0 (it) 2000-04-26
DK200000677A (da) 2000-10-31
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
MXPA00003997A (es) 2002-03-08
EP1415652A2 (en) 2004-05-06
DE60005940T3 (de) 2015-08-27
GR20000100153A (el) 2000-12-29
HUP0001632A2 (hu) 2001-05-28
SI1173181T1 (en) 2004-04-30
ES2208317T7 (es) 2015-09-15
DE10021266A1 (de) 2000-11-16
WO2000066099A3 (en) 2001-01-18
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
DK1173181T6 (en) 2015-04-27
ATE251908T1 (de) 2003-11-15
CA2371684C (en) 2007-10-23
BR0003046A (pt) 2002-07-23
GR1003575B (el) 2001-05-14
WO2000066099A2 (en) 2000-11-09
DZ3171A1 (tr) 2000-11-09
NZ514882A (en) 2003-08-29
IE20000315A1 (en) 2001-03-07
MXPA01010837A (es) 2002-11-07
HU230369B1 (hu) 2016-03-29
EA200000355A2 (ru) 2000-10-30
EP1173181A2 (en) 2002-01-23
DE20007861U1 (de) 2000-08-24
HUP0001632A3 (en) 2001-12-28
KR20020008396A (ko) 2002-01-30
PT102457A (pt) 2000-11-30
PE20010071A1 (es) 2001-03-22
CA2307101A1 (en) 2000-10-30
PL352629A1 (en) 2003-08-25
AU769946C (en) 2005-01-13
EP1173181B1 (en) 2003-10-15
NO20015275D0 (no) 2001-10-29
TR200001132A3 (tr) 2001-01-22
JP2000336043A (ja) 2000-12-05
SE0001518D0 (sv) 2000-04-26
LV12560B (en) 2001-04-20
HRP20000243A2 (en) 2001-12-31
GB0010199D0 (en) 2000-06-14
IL146098A0 (en) 2002-07-25
IL146098A (en) 2007-06-03
EA200000355A3 (ru) 2001-02-26
KR20010020779A (ko) 2001-03-15
PL339897A1 (en) 2000-11-06
LU90569B1 (fr) 2002-02-27
ZA200108900B (en) 2003-03-26
PL197813B1 (pl) 2008-04-30
BE1012957A5 (fr) 2001-06-05
CH692478A5 (de) 2002-07-15
CA2371684A1 (en) 2000-11-09
DK1173181T3 (da) 2004-02-16
HK1041204B (en) 2004-03-05
CN1292264A (zh) 2001-04-25
UA72248C2 (en) 2005-02-15
CZ296534B6 (cs) 2006-04-12
DE60005940T2 (de) 2004-07-29
NO20002097D0 (no) 2000-04-25
NZ504163A (en) 2001-11-30
SK15632001A3 (sk) 2002-02-05
LT4758B (lt) 2001-02-26
ITMI20000922A1 (it) 2001-10-26
AU769946B2 (en) 2004-02-12
LT2000035A (lt) 2000-11-27
FR2795646A1 (fr) 2001-01-05
FI20000976A7 (fi) 2000-10-30
HUP0200912A2 (en) 2002-08-28
ES2208317T3 (es) 2004-06-16
AU2004201988A1 (en) 2004-06-10
ID25704A (id) 2000-11-02
EP1415652A3 (en) 2004-05-12
EA200101008A1 (ru) 2002-04-25
JP4975214B2 (ja) 2012-07-11

Similar Documents

Publication Publication Date Title
TR200001132A2 (tr) İmalat maddeleri
ATE231501T1 (de) Phenyldihydrobenzofurane
ATE230404T1 (de) Cyclohexyldihydrobenzofurane
EA200201011A1 (ru) Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction